Evidence map›Paper›PMID 39197870›Full record

Trial reportRespirology (Carlton, Vic.)2025

Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII).

Changhao Zhong, Enguo Chen, Zhuquan Su, Difei Chen, Feng Wang, Xiaoping Wang, Guangnan Liu, Xiaoju Zhang, Fengming Luo, Nan Zhang and 12 more

Abstract readMulticenter StudyClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Respirology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Changhao ZhongState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, People's Republic of China.
Enguo ChenDepartment of Respiratory and Critical Care Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Zhejiang, Hangzhou, People's Republic of China.
Zhuquan SuState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, People's Republic of China.ORCID 0000-0002-5583-0349
Difei ChenState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, People's Republic of China.ORCID 0000-0002-9587-6501
Feng WangDepartment of Respiratory and Critical Care Medicine, Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, People's Republic of China.ORCID 0000-0002-2429-5662
Xiaoping WangDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Chest Hospital, Jinan, Shandong, People's Republic of China.
Guangnan LiuDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Xiaoju ZhangDepartment of Respiratory and Critical Care Medicine, Henan Province People Hospital, Zhengzhou, Henan, People's Republic of China.
Fengming LuoDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.
Nan ZhangDepartment of Respiratory and Critical Care Medicine, Emergency General Hospital, Beijing, People's Republic of China.
Hongwu WangDepartment of Respiratory and Critical Care Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China.ORCID 0000-0001-6401-977X
Longyu JinDepartment of Respiratory and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
Fa LongDepartment of Respiratory and Critical Care Medicine, University of Chinese Academy of Sciences Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China.
Chunfang LiuDepartment of Respiratory and Critical Care Medicine, DaLian Municipal Central Hospital, Dalian, Liaoning, People's Republic of China.
Shiman WuDepartment of Respiratory and Critical Care Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Qing GengDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.ORCID 0000-0003-4515-5084
Xiang WangDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
Chunli TangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, People's Republic of China.
Ruchong ChenState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, People's Republic of China.
Felix J F HerthDepartment of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-7638-2506
Jiayuan SunDepartment of Respiratory Endoscopy and Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai, People's Republic of China.
Shiyue LiState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, People's Republic of China.

Funding

Guangdong special support plan projectGuangzhou Science and Technology Plan Project 202103010001
6 · The paper itself

Abstract

BACKGROUND AND

objectiveRadiofrequency ablation (RFA) is an emerging treatment of lung cancer, yet it is accompanied by certain safety concerns and operational limitations. This first multi-centre, large-scale clinical trial aimed to investigate the technical performance, efficacy and safety of an innovative transbronchial RFA system for lung tumours.

methodsThe study enrolled patients with malignant lung tumours who underwent transbronchial RFA using an automatic saline microperfusion system between January 2021 and December 2021 across 16 medical centres. The primary endpoint was the complete ablation rate. The performance and safety of the technique, along with the 1-year survival rates, were evaluated.

resultsThis study included 126 patients (age range: 23-85 years) with 130 lung tumours (mean size: 18.77 × 14.15 mm) who had undergone 153 transbronchial RFA sessions, with a technique success rate of 99.35% and an average ablation zone size of 32.47 mm. At the 12-month follow-up, the complete ablation rate and intrapulmonary progression-free survival rates were 90.48% and 88.89%, respectively. The results of patients with ground-glass nodules (GGNs) were superior to those of the patients with solid nodules (12-month complete ablation rates: solid vs. pure GGN vs. mixed GGN: 82.14% vs. 100% vs. 96.08%, p = 0.007). No device defects were reported. Complications such as pneumothorax, haemoptysis, pleural effusion, pulmonary infection and pleural pain were observed in 3.97%, 6.35%, 8.73%, 11.11% and 10.32% of patients, respectively. Two subjects died during the follow-up period.

conclusionTransbronchial RFA utilizing an automatic saline microperfusion system is a viable, safe and efficacious approach for the treatment for lung tumours, particularly for patients with GGNs.

Indexed as

Lung NeoplasmsRadiofrequency AblationAdultAgedAged, 80 and overBronchoscopyCatheter AblationFemaleFollow-Up StudiesHumansMaleMiddle AgedSurvival RateTreatment OutcomeYoung Adultbronchoscopyground‐glass nodulelung tumourradiofrequency ablation

Identifiers

PMID39197870
PMCPMC11688625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.